NeuroSense Therapeutics Ltd.
NRSN
Positions held
Your positionsNRSN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $6.79M | Enterprise value | $6.33M | Trailing P/E | — | Forward P/E | -0.30 |
| PEG | — | Price / book | -3.74 | Beta | 1.64 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -21.7% | ROA | -2.5% | Debt / equity | — |
| Current ratio | 0.31 | Free cash flow | -$3.87M | Analyst recommendation | strong_buy | Mean target | $97.33 |
| 52w high | $26.64 | 52w low | $3.56 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$11.1M | -$10.2M | -$10.1M | -$10.5M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$11.1M | -$9.9M | -$12.0M | -$10.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Neurosense Therapeutics Receives Nasdaq Listing Compliance Notice
2026-10-02 · NeuroSense Provides Update on Nasdaq Listing Compliance
2026-09-28 · NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
2026-09-25 · NeuroSense Provides Business Update and Progress for the First Half of 2026
2026-09-10 · NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-08-31 · NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
2026-08-13 · NeuroSense Issues CEO Letter to Shareholders
2026-08-06 · NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
2026-07-22 · NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
Price (daily)
Full chart · RSI · MACD · patterns